Company Overview and News


Add PVA
to your dashboard

Headline News

BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

2017-07-10 reuters
* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation

pSivida's Eye Drug/Device Hits Goals in Second Late-Stage Study

2017-06-13 biospace
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence

pSivida's Eye Drug/Device Hits Goals in Second Late-Stage Study

2017-06-13 devicespace
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence

pSivida Release; Durasert Three-Year Treatment For Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months

2017-05-08 devicespace
pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in June 2017

pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th

2017-04-20 finance.yahoo
WATERTOWN, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the third quarter of fiscal year 2017 will be released after the market close on Thursday, May 4, 2017, followed the same day by a conference call and live webcast scheduled for 4:30 p.

pSivida Corp. appoints Nancy Lurker chief executive officer

2016-09-16 proactiveinvestors.com.au
pSivida Corp. (ASX:PVA, NASDAQ:PSDV) has appointed Nancy Lurker as its president and chief executive officer and a member of the board of directors. U.S. based pSivida Corp is a dual listed leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. From 2008 to 2015, Lurker served as chief executive officer and a director of PDI, Inc.

pSivida Corp. achieves efficacy in uveitis trials with unique device

2016-08-10 proactiveinvestors.com.au
pSivida Corp. (ASX:PVA, NASDAQ:PSDV) has met the primary endpoint in utilization study of its new, proprietary 27-gauge inserter ‘Medidur’ for posterior uveitis, an inflammatory disease affecting the eye. Medidur is a miniaturised, injectable, sustained-release drug delivery system designed to treat posterior uveitis. In the study, 66% of injections using the new 27-gauge inserter achieved a satisfactory rating of “Routine,” “Easy” or “Very Easy” while only 46% of injections utilizing the earlier, larger 25-gauge inserter used in the first Medidur Phase 3 trial met that standard.

Appendix 3B

2016-05-05 asx.com.au

Appendix 3B

2016-04-06 asx.com.au

3 Life Sciences Tools & Services Stocks to Sell Now

2016-03-24 investorplace
This week, 3 Life Sciences Tools & Services stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

pSivida CEO Acquires Shares

2016-03-23 asx.com.au

Appendix 3B

2016-03-02 asx.com.au

pSivida Form EX-24.2

2016-02-13 sec.gov
EX-24.2 EXHIBIT 24-2 POWER OF ATTORNEY I hereby constitute and appoint Sarah L. Filion, as my true and lawful attorney-in-fact to:     (1) execute for and on my behalf, in my capacity as a member of North Run Advisors, LLC and in my individual capacity, statements of beneficial ownership required to be filed with the Securities and Exchange Commission on Schedule 13G, together with any amendments thereto and all joint filing agreements filed therewith, by North Run Capital, LP, North Run GP, LP,

pSivida Form EX-24.1

2016-02-13 sec.gov
EX-24.1 EXHIBIT 24-1 POWER OF ATTORNEY I hereby constitute and appoint Sarah L. Filion, as my true and lawful attorney-in-fact to:     (1) execute for and on my behalf, in my capacity as a member of North Run Advisors, LLC and in my individual capacity, statements of beneficial ownership required to be filed with the Securities and Exchange Commission on Schedule 13G, together with any amendments thereto and all joint filing agreements filed therewith, by North Run Capital, LP, North Run GP, LP,

pSivida Form SC 13G/A (Acquisition of More Than 5% of Shares)

2016-02-13 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     SCHEDULE 13G/A (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934     pSivida Corp. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 74440J101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Stat

Final Director's Interest Notice

2016-02-11 asx.com.au

pSivida Form 8-K (Current Report/Significant Event)

2016-02-10 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2016     pSivida Corp. (Exact name of registrant as specified in its charter)       Delaware   000-51122   26-2774444 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

pSivida Form EX-101.LAB

2016-02-10 sec.gov
Accounts and Other Receivables, Net, Current Accounts and other receivables Accounts receivable Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accrued clinical expense current. Accrued Clinical Expense Current Clinical trial costs Accrued Liabilities, Current Accrued expenses Accrued expenses Accrued Professional Fees, Current Professional fees Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other